Article Text

Download PDFPDF

6ER-012 Efficacy and safety analysis of alemtuzumab in relapsing-remitting multiple sclerosis
Free
  1. M Murillo Izquierdo,
  2. I Castañeda Macías,
  3. M Vázquez-Real,
  4. L Rendón De Lope,
  5. J Cordero Ramos,
  6. C Castillo Martín
  1. Hospital Universitario Virgen Macarena, Pharmacy Department, Seville, Spain

Abstract

Background Alemtuzumab is a humanised monoclonal antibody against CD52 approved for relapsing-remitting multiple sclerosis (RRMS), which is a progressive illness affecting the central nervous system (CNS).

Purpose The objective of the present study was to evaluate the efficacy and safety of alemtuzumab.

Material and methods A retrospective study was carried out in a university hospital. Patients treated with alemtuzumab were included for the November 2016–November 2017 period. Data was drawn from clinical digital history and visits from the outpatients module. Demographic data (age, gender), clinical data (diagnosis, previous treatments, number of cycles, Expanded Disability Status Scale (EDSS) before and after treatment, number of relapses since the start of alemtuzumab, MRI lesions’ evolution) and safety data (adverse events (AE), blood tests) were registered.

Results Twenty-five patients were found, 20 (80%) of whom were females. Mean age was 41.5 (±9.3). Twenty-three patients (92%) had a diagnosis of RRMS, one (4%) secondary progressive and one (4%) primary progressive. All patients went through the second infusion cycle during the studied period. Twenty-one patients (84%) had received a mean of the previous treatments of 1.9 (±1.1), the rest of them were naïve. Mean EDSS before treatment was 4.7 (±1.7) and after was 3.5 (±2). Between the first and second cycle (1 year), none of them had a relapse. Confirmed by MRI, 16 patients (64%) had a reduction in CNS lesions and six (24%) had no change. The most reported AE during infusion were migraine: 14/25 patients; rash: 9/25 patients; fever: 5/25 patients; pruritus: 3/25 patients; and hypotension 3/25 patients. After infusion, the most reported AE were rash: 12/25, asthaenia: 6/25, upper respiratory infection: 5/25, candidiasis: 4/25 and insomnia: 4/25. In blood tests, 100% had lymphopaenia, with a mean duration of 6.3 months (±3.7) after the first cycle and 4.9 months (±2.9) after the second cycle.

Conclusion Alemtuzumab seems to be an effective treatment for RRMS as shown by the reduction in EDSS before and after treatment, any relapse between cycles in our population and lesion reduction in the 64% of patients and no change in 24% of patients. Most of the AE were mild, with migraine being more prevalent during infusion and rash after it.

References and/or acknowledgements https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522829/

No conflict of interest.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.